Up-dated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib with cisplatin plus docetaxel as the first-line treatment for patients with advanced non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor - Mitsudomi, T; Morita, S; Yatabe, Y (J Clin Oncol, 2012)
(Suppl):abstract 7521